Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

notreload_ai Jun. 15 at 5:00 PM

CMS has proposed making its Medicare Drug Price Negotiation Program permanent from 2029, tightening rules on combo drugs. $JNJ, $BMY, and $MRK shares fell on the news, but analysts see limited long-term impact due to legal challenges and diversification. https://notreload.xyz/xy/cms-to-make-medicare-drug-price-negotiations-permanent-in-2029/

0 · Reply

MorganHoratio Jun. 15 at 4:41 PM

Here are some of the most prominent themes that our team is focusing on: Healthcare: $OSCR $HNGE $UNH $JNJ $HTFL This Healthcare watchlist captures the vital rotating theme of mid-2026: smart money is spilling out of legacy defensive value into high-pricing-power digital health and clinical AI disruptors. The underlying fundamentals here are stellar. Digital MSK leader $HNGE just hiked its full-year 2026 growth outlook to a rampant 40% at its June 10 Investor Day. Meanwhile, AI coronary pioneer $HTFL raised its fiscal guidance following a blowout 41% YoY Q1 revenue jump on rapid product adoption. Concurrently, insurtech leader $OSCR is holding multi-year highs, while legacy staples like $UNH (navigating its recent FTC insulin settlement) and $JNJ reset to deep structural support. Are you sheltering in cash-cow defensive giants like $UNH, or accumulating high-growth AI health turnarounds like $HNGE and $HTFL on this necessary dip?

0 · Reply

clan Jun. 15 at 4:24 PM

$MNKD For the good of all Mannkind. Ignore the whiny lying trolls🧌. 2026 is Mannkind's "year of inflection". Think hockey stick 🏒 ...and multiple shots on goal🥅. $SPY $QQQ $JNJ

0 · Reply

RunnerSignals Jun. 15 at 3:20 AM

Goldman screen $IOT $BTSG $ULTA $JNJ everyone sees the ai trade. the more interesting signal is where analysts are finding durable growth, margin expansion worth watching where institutional flows are concentrating. https://stocksrunner.com/news/2026-06-14-goldman-sachs-highlights-stocks-positioned-to-lead-the-market

0 · Reply

AdamBrennan2 Jun. 15 at 2:01 AM

$LLY pricing in 16.6% free cash flow growth, i think the growth will be much more than this with reta $NVO $JNJ $ABBV $NVS

0 · Reply

AStrokeOfLuck Jun. 13 at 2:51 PM

$JNJ $AMGN $PFE $MRK $BMY

0 · Reply

focafoca99 Jun. 13 at 10:45 AM

$JNJ announced strong Phase 3 MonumenTAL-3 data, with TALVEY + DARZALEX FASPRO achieving up to 81% PFS and 89% OS at 24 months. https://www.rapidticker.com/news/jnj-new-talvey-talquetamab-tgvs-plus-1ffcd0

0 · Reply

topstockalerts Jun. 12 at 8:47 PM

Leerink reported a rebound in U.S. prescription trends for the week ended June 5, 2025, with the overall pharmaceutical market growing 10% week-over-week after an 8% decline during the Memorial Day period. Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) posted prescription growth of 46% year-over-year over one week, 51% over four weeks, and 57% over 12 weeks. Novo Nordisk's semaglutide products (Ozempic/Wegovy) recorded growth of 22%, 21%, and 18%, respectively. Wegovy prescriptions rose 10% week-over-week, while Zepbound increased 9%. Foundayo generated roughly 20,000 prescriptions in its ninth week on the market, up 17% sequentially but still well below oral Wegovy's approximately 81,000 prescriptions during its ninth week. Oral Wegovy reached around 159,000 prescriptions in its 22nd launch week, although Leerink noted IQVIA data likely understates demand by excluding certain direct-to-consumer channels. $LLY $NVO $ABBV $JNJ

0 · Reply

P0rNsTaR Jun. 12 at 3:49 PM

$ABVX gearing up for that afternoon recovery to green. $LLY $JNJ

1 · Reply

flordi Jun. 12 at 2:26 PM

$JNJ when 250 again?

1 · Reply

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

2026-06-15T10:05:07.000Z - 10 hours ago

Johnson & Johnson invests more than $1B in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 10 hours ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 2 days ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 2 days ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

2026-06-11T11:50:10.000Z - 4 days ago

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Jun 11, 2026, 7:45 AM EDT - 4 days ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 4 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

2026-06-11T09:26:54.000Z - 4 days ago

Johnson & Johnson presents first results from ENERGY study

Jun 11, 2026, 2:03 AM EDT - 4 days ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 5 days ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 5 days ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 6 days ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 6 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 7 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

2026-06-08T13:00:56.000Z - 7 days ago

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

2026-06-08T12:14:56.000Z - 7 days ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash

Jun 8, 2026, 8:08 AM EDT - 7 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 7 days ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 9 days ago

J&J beats lawsuit alleging that talc caused three women's cancer

2026-06-03T09:38:11.000Z - 12 days ago

Johnson & Johnson presents exploratory analyses from DAHLIAS study

2026-06-03T09:31:04.000Z - 12 days ago

Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study

Jun 3, 2026, 12:04 AM EDT - 12 days ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 12 days ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 12 days ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

2026-05-31T21:41:49.000Z - 14 days ago

Johnson & Johnson announces Phase 3 Proteus study met primary endpoints

2026-05-31T21:40:07.000Z - 14 days ago

Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study

May 31, 2026, 8:39 AM EDT - 15 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 15 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 15 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 15 days ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 17 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 8:18 AM EDT - 17 days ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 17 days ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 18 days ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 19 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 19 days ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 25 days ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 25 days ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 27 days ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 27 days ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 4 weeks ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

May 12, 2026, 2:20 PM EDT - 4 weeks ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 4 weeks ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 5 weeks ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 5 weeks ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 5 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 5 weeks ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 5 weeks ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 5 weeks ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 6 weeks ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 6 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 6 weeks ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 6 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 7 weeks ago

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 8:03 AM EDT - 7 weeks ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 7 weeks ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 23, 2026, 6:44 PM EDT - 7 weeks ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Apr 23, 2026, 10:00 AM EDT - 7 weeks ago

Johnson & Johnson Transcript: AGM 2026

Apr 22, 2026, 8:05 AM EDT - 7 weeks ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 4:00 AM EDT - 7 weeks ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 21, 2026, 4:22 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

notreload_ai Jun. 15 at 5:00 PM

0 · Reply

MorganHoratio Jun. 15 at 4:41 PM

0 · Reply

clan Jun. 15 at 4:24 PM

$MNKD For the good of all Mannkind. Ignore the whiny lying trolls🧌. 2026 is Mannkind's "year of inflection". Think hockey stick 🏒 ...and multiple shots on goal🥅. $SPY $QQQ $JNJ

0 · Reply

RunnerSignals Jun. 15 at 3:20 AM

0 · Reply

AdamBrennan2 Jun. 15 at 2:01 AM

$LLY pricing in 16.6% free cash flow growth, i think the growth will be much more than this with reta $NVO $JNJ $ABBV $NVS

0 · Reply

AStrokeOfLuck Jun. 13 at 2:51 PM

$JNJ $AMGN $PFE $MRK $BMY

0 · Reply

focafoca99 Jun. 13 at 10:45 AM

0 · Reply

topstockalerts Jun. 12 at 8:47 PM

0 · Reply

P0rNsTaR Jun. 12 at 3:49 PM

$ABVX gearing up for that afternoon recovery to green. $LLY $JNJ

1 · Reply

flordi Jun. 12 at 2:26 PM

$JNJ when 250 again?

1 · Reply

LibertarianTreehugger Jun. 12 at 12:29 PM

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend: https://www.fool.com/investing/2026/06/12/abbvie-reports-promising-new-clinical-updates-here/ $ABBV $JNJ $AMGN $LLY

0 · Reply

ElliottwaveForecast Jun. 12 at 11:42 AM

$JNJ Are you long from #bluebox area? It favors rally targerting 259.3 or higher to extend January-2025 sequence, while dips remain above 5.11.2026 low. Buyers from #Bluebox area already got risk free position as it reacted more than 50 % of (Y) leg. #Elliottwave #JNJ

0 · Reply

AcceleratorModel Jun. 12 at 7:23 AM

$JNJ looks good on short term time periods like 3m, YTD, even 1yr All time chart saying that JNJ hasn’t pulled a 12mo move like this since ‘00

0 · Reply

red_bull7 Jun. 12 at 12:35 AM

$AMGN This is gonna rip higher in the coming days. It's coming out of that slow rolling base with a break of the descending trend line and a successful retest on higher volume. $MRK $JNJ $LLY

0 · Reply

Quantumup Jun. 11 at 8:19 PM

Stifel on $ORIC said: We resume coverage of ORIC Pharmaceuticals with a Buy Rating and a $14 target price. $PFE $JNJ IPSEY DSNKY Stifel added—ORIC's lead asset, rinzimetostat, is a PRC2 complex inhibitor being developed in combination with darolutamide in metastatic castration resistant prostate cancer (mCRPC) — a Ph3 clinical trial (Himalayas-1) is expected to initiate in June/July 2026 in mCRPC patients previously treated with abiraterone. Logic for the combination is PRC2 inhibition blocks/reverts epigenetic reprogramming, resensitizing prostate cancer cells to androgen receptor pathway inhibitors (ARPIs) like darolutamide. ORIC has cash runway out to 2H28, getting them through Himalayas-1 top-line data expected in early 2028.

0 · Reply

Wallstfan Jun. 11 at 4:01 PM

$JNJ this is why you buy quality names over hype. Most likely gonna be at $250 soon

0 · Reply

CointegrationX Jun. 11 at 3:15 PM

$JNJ remains focused on healthcare innovation, pharmaceuticals, and medical technologies. RMTG reported strong demand for regenerative medicine training and clinic support services.

0 · Reply

Trader_Ty Jun. 11 at 2:41 PM

$JNJ Will add on a dip for the bull flag breakout trade

0 · Reply

Estimize Jun. 11 at 2:12 PM

Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont

0 · Reply

Diefreeandsell Jun. 11 at 12:34 PM

$IBRX $XBI $MRK $JNJ $TNA Once cross over minor res @7.15 next res is easy to get to next level that takes it over $7.5. Self reinforcing loop by MM's . KNicks pulled it off, so will IBRX!!!

0 · Reply

ElliottwaveForecast Jun. 11 at 9:07 AM

$JNJ Buyers from #Bluebox area looking for rally targeting above 259.3 or higher It was expected double correction to finish in #Bluebox between 227.8 - 215.82 area for next rally within January-2025 rally. It ended as anticipated and reacting higher now. #Elliottwave #JNJ

0 · Reply

mikesterz7 Jun. 11 at 6:55 AM

$JNJ 🚨🚨🚨 Johnson & Johnson reported pivotal Phase 2/3 ENERGY data for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, a disease with no FDA-approved therapies. The 30 mg/kg group achieved statistically significant durable hemoglobin response and about three times more responders than placebo by 24 weeks. Mean hemoglobin rose ≥1 g/dL by Week 1, nearly two-thirds met stringent hemoglobin targets by Week 24, fatigue and corticosteroid use improved, safety matched the existing profile, and the sBLA has FDA Priority Review.

0 · Reply

Market Cap	579.83B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.21
Forward PE	20.60
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	4,063,585
Avg Vol	7,638,250
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	96%
Beta	0.26
Analysts	Strong Sell
Price Target	$260.46